Leptoprol

Leuprorelin, the active ingredient in Leptoprol, is a Gonadotropin‑releasing hormone (GnRH) agonist presented as a subcutaneous injection for subcutaneous use. It treats hormone‑dependent conditions such as prostate cancer, endometriosis, breast cancer, precocious puberty and uterine fibroids in adult patients.

GNH USA supplies Leptoprol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Leuprorelin acts on the GnRH pathway to control hormone‑driven diseases. - Prostate cancer: suppresses testosterone production to inhibit tumor progression. - Endometriosis: reduces estrogen levels, alleviating pelvic pain and lesion growth. - Breast cancer: lowers circulating estrogen, supporting hormone‑responsive tumor control. - Precocious puberty: delays early sexual development by inhibiting gonadotropin release. - Uterine fibroids: diminishes estrogen stimulation, leading to fibroid size reduction.

Leuprorelin may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Injection site reactions: pain, redness or swelling at the injection site. - Headache: mild to moderate intensity. - Fatigue: generalized tiredness. - Nausea: occasional upset stomach. - Mood changes: irritability or depressive symptoms.

Serious or Rare Side Effects: - Bone loss: decreased bone mineral density leading to osteoporosis. - Cardiovascular events: increased risk of thromboembolism or hypertension. - Severe allergic reaction: anaphylaxis or angioedema. - Pituitary apoplexy: sudden hemorrhage in the pituitary gland. - Liver dysfunction: abnormal liver enzymes or hepatitis.

Leuprorelin requires careful monitoring and patient counseling. - Monitor hormone levels: assess LH, FSH and sex steroid concentrations regularly. - Assess bone health: perform baseline and periodic bone density scans. - Evaluate cardiovascular risk: screen for hypertension, clotting disorders and lipid abnormalities. - Contraindicate in pregnancy: avoid use in women who are or may become pregnant. - Adjust for hepatic impairment: consider dose modification in patients with liver dysfunction. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Leuprorelin can interact with several drug classes.

Major Interactions (Avoid): - Hormonal contraceptives: reduced efficacy, increasing risk of unintended pregnancy. - Estrogen replacement therapy: heightened thromboembolic risk. - Strong CYP3A4 inhibitors: potential alteration of leuprorelin metabolism.

Moderate Interactions (Monitor Closely): - Antidepressants: may exacerbate mood changes. - Bisphosphonates: monitor bone density when used together. - Certain chemotherapeutic agents: adjust dosing based on overlapping toxicities.